重组人血管内皮抑制素联合常规化疗进行非小细胞肺癌术后辅助化疗的临床疗效探讨

目的研究重组人血管内皮抑制素（恩度）联合常规化疗方案对非小细胞肺癌（NSCLC）术后辅助化疗的临床疗效。方法选择经病理确诊、行根治性手术的NSCLC患者50例，随机分为两组，各25例。治疗组予恩度分别联合GP、TP、NP方案治疗；对照组予单用GP或TP或NP方案治疗。两组患者均于术后4周开始治疗，3周为1个周期，4个周期结束后评价疗效。结果所有患者治疗后外周血中循环血管内皮细胞（CEC）、癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE），细胞角蛋白19片段（CYFR21—1）水平均较治疗前明显下降，第4周期时治疗组CEC、NSE、CYFR21—1下降程度明显大于对照组，差异有统计学意义（P〈0．05或P〈0．01）；治疗组有效率（RR）及临床受益率（CBR）均高于对照组，CBR差异有统计学意义（P〈0．05）；两组患者不良反应发生率比较，差异无统计学意义（P〉0．05）。结论恩度联合常规化疗对NSCLC患者进行术后辅助治疗的近期及远期疗效均优于单用化疗，并可显著降低CEC、CEA、NSE、CYFR21—1水平，且安全性良好。

Clinical Effect of Recombinant Human Endostatin Combined with Routine Chemotherapy on Postoperative Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer

Objective To explore the clinical effect of recombinant human endostatin（endostar）combined with routine chemotherapy on postoperative adjuvant chemotherapy for non-small-cell lung cancer（NSCLC）. Methods 50 cases of NSCLC who were diagnosed by pathology and after radical surgery were divide into two groups. The treatment group（n= 25）received endostar combined with GP or TP or NP regimen. The control group（n= 25） received GP or TP or NP regimen alone. The treatment began four weeks after surgery. Three weeks were as one course. The clinical effects were measured after four courses. Results The levels of CEC, CEA, NSE, CYFR21-1 after treatment obviously decreased than that before treatment. At the fourth course, the decreasing degrees in treatment group were obviously higher than that in control group（P〈0. 05 or P〈0. 01 ）. The RR and CBR in treatment group were higher than that in control group, and the differences of CBR between the two groups had statistical significance（P〈0.05 ）. There was no statistical difference of adverse reactions between the two groups（P〉0.05）. Conclusions The recent and long-term clinical effects of endostar combined with routine chemotherapy on adjuvant chemotherapy for NSCLC were better than that of routine chemotherapy alone. It can obviously decrease the levels of CEC,CEA,NSE,CYFR21-1 and has well security.